[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,617
  • Shares Outstanding, K 119,354
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,760 K
  • EBIT $ -24 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $-0.08 on 05/14/26
  • Next Earnings Date 08/14/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 2
  • High Estimate $-0.03
  • Low Estimate $-0.06
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7700 +5.13%
on 05/20/26
1.1700 -30.81%
on 04/27/26
-0.3405 (-29.61%)
since 04/22/26
3-Month
0.7700 +5.13%
on 05/20/26
1.1900 -31.97%
on 02/24/26
-0.1545 (-16.03%)
since 02/20/26
52-Week
0.3258 +148.47%
on 06/06/25
1.5100 -46.39%
on 09/29/25
+0.4076 (+101.42%)
since 05/22/25

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announces that translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American ...

ONCY : 0.8095 (+2.47%)
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational...

ONCY : 0.8095 (+2.47%)
Stocks in play: Oncolytics Biotech Inc

Announced new durability data in metastatic colorectal cancer, demonstrating meaningful and sustained ...

ONCY : 0.8095 (+2.47%)
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in...

ONCY : 0.8095 (+2.47%)
Stocks in play: Oncolytics Biotech Inc

Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment ...

ONCY : 0.8095 (+2.47%)
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient...

ONCY : 0.8095 (+2.47%)
Stocks in play: Oncolytics Biotech Inc

Announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration on April 16, ...

ONCY : 0.8095 (+2.47%)
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...

ONCY : 0.8095 (+2.47%)
Stocks in play: Oncolytics Biotech Inc

Announced the completion of the previously announced change in the jurisdiction of incorporation of ...

ONCY : 0.8095 (+2.47%)
Oncolytics Biotech® Completes Domicile Change to the United States

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.8095 (+2.47%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 0.8490
2nd Resistance Point 0.8344
1st Resistance Point 0.8220
Last Price 0.8095
1st Support Level 0.7950
2nd Support Level 0.7804
3rd Support Level 0.7680

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Fibonacci 50% 0.9179
Last Price 0.8095
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.